CN111868036A - 杂环p2y14受体拮抗剂 - Google Patents

杂环p2y14受体拮抗剂 Download PDF

Info

Publication number
CN111868036A
CN111868036A CN201980012696.0A CN201980012696A CN111868036A CN 111868036 A CN111868036 A CN 111868036A CN 201980012696 A CN201980012696 A CN 201980012696A CN 111868036 A CN111868036 A CN 111868036A
Authority
CN
China
Prior art keywords
compound
esi
mmol
phenyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980012696.0A
Other languages
English (en)
Chinese (zh)
Inventor
肯尼思·A·雅各布森
柳真贺
安东内拉·钱切塔
温志伟
郑瑛焕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN111868036A publication Critical patent/CN111868036A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980012696.0A 2018-02-09 2019-02-11 杂环p2y14受体拮抗剂 Pending CN111868036A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628699P 2018-02-09 2018-02-09
US62/628,699 2018-02-09
PCT/US2019/017422 WO2019157417A1 (en) 2018-02-09 2019-02-11 Heterocyclic p2y14 receptor antagonists

Publications (1)

Publication Number Publication Date
CN111868036A true CN111868036A (zh) 2020-10-30

Family

ID=65529813

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980012696.0A Pending CN111868036A (zh) 2018-02-09 2019-02-11 杂环p2y14受体拮抗剂

Country Status (7)

Country Link
US (1) US11584736B2 (https=)
EP (1) EP3749651A1 (https=)
JP (1) JP2021512898A (https=)
CN (1) CN111868036A (https=)
AU (1) AU2019218256A1 (https=)
CA (1) CA3090788A1 (https=)
WO (1) WO2019157417A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116444482A (zh) * 2023-06-14 2023-07-18 中国药科大学 噻吩-2-羧酸衍生物、其制备方法及医药用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11708346B2 (en) 2019-07-23 2023-07-25 Saint Louis University Treatment and prevention of neuropathic pain with P2Y14 antagonists
WO2022155037A1 (en) * 2021-01-18 2022-07-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Heterocyclic p2y 14 receptor antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064385B1 (en) * 1981-04-30 1986-04-02 The Upjohn Company 2,6-diaryl-pyridinecarboxylic acids and their therapeutic utility
WO2007025575A1 (en) * 2005-04-08 2007-03-08 Smithkline Beecham Corporation O-hydroxy- and o-amino benzamide derivatives as ikk2 inhibitors
US20130018189A1 (en) * 2010-12-13 2013-01-17 Yun Chi 2-phenyl-6-azolylpyridine-based ligand and group viii transition metal complex

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2706632A1 (en) * 2007-12-04 2009-06-11 Merck Frosst Canada Ltd. Substituted 2-naphthoic acids as antagonists of gpr105 activity
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
DE112011105485T5 (de) 2011-08-01 2014-06-12 Mitsubishi Electric Corporation Steuervorrichtung und Steuerverfahren für eine Spritzgussmaschine
EP2774919A1 (en) 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Novel sulfonamide TRPA1 receptor antagonists
PE20181366A1 (es) * 2015-08-03 2018-08-27 Bristol Myers Squibb Co Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa
US10683277B2 (en) 2015-09-25 2020-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Triazole derivatives as P2Y14 receptor antagonists
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US11938114B2 (en) 2017-03-10 2024-03-26 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
CN109096177A (zh) 2018-08-31 2018-12-28 中国药科大学 3－酰胺基苯甲酸衍生物、其制备方法及医药用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064385B1 (en) * 1981-04-30 1986-04-02 The Upjohn Company 2,6-diaryl-pyridinecarboxylic acids and their therapeutic utility
WO2007025575A1 (en) * 2005-04-08 2007-03-08 Smithkline Beecham Corporation O-hydroxy- and o-amino benzamide derivatives as ikk2 inhibitors
US20130018189A1 (en) * 2010-12-13 2013-01-17 Yun Chi 2-phenyl-6-azolylpyridine-based ligand and group viii transition metal complex

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNA JUNKER ET AL.: "Structure-Based Design of 3‑(4-Aryl‑1H‑1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists" *
COLUMBUS，OHIO: "US REGISTRY[Online]" *
JACQUES YVES GAUTHIER ET AL.: "The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14" *
MATTHEW O. BARRETT ET AL.: "A Selective High-Affinity Antagonist of the P2Y14 Receptor Inhibits UDP-Glucose–Stimulated Chemotaxis of Human Neutrophils" *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116444482A (zh) * 2023-06-14 2023-07-18 中国药科大学 噻吩-2-羧酸衍生物、其制备方法及医药用途
CN116444482B (zh) * 2023-06-14 2023-09-22 中国药科大学 噻吩-2-羧酸衍生物、其制备方法及医药用途
WO2024255920A1 (zh) * 2023-06-14 2024-12-19 中国药科大学 噻吩-2-羧酸衍生物、其制备方法及医药用途

Also Published As

Publication number Publication date
JP2021512898A (ja) 2021-05-20
WO2019157417A1 (en) 2019-08-15
US11584736B2 (en) 2023-02-21
AU2019218256A1 (en) 2020-08-20
CA3090788A1 (en) 2019-08-15
EP3749651A1 (en) 2020-12-16
US20210047293A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
US11851440B2 (en) Modulators of eukaryotic initiation factor 2B, compositions and methods
CN110248939B (zh) 作为rho-激酶抑制剂的酪氨酸酰胺衍生物
CN107428696B (zh) 磺酰脲和相关化合物及其用途
CN111148746B (zh) 杂环化合物
CN103180326B (zh) 杂环化合物及其用途
AU2014248763B2 (en) Substituted piperidine compounds and their use as orexin receptor modulators
JP6242390B2 (ja) Ｃｓｆ−１ｒキナーゼ阻害剤としての２−アミノピラジン誘導体
JP2020515575A (ja) ヘテロ環化合物
CN105683188A (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
TW200932743A (en) Azole carboxamide compounds or salts thereof
US20220363694A1 (en) N-cyano-7-azanorbornane derivatives and uses thereof
WO2016189876A1 (en) Urea derivative or pharmacologically acceptable salt thereof
JP7030802B2 (ja) ナフチリジノン誘導体および不整脈の治療におけるそれらの使用
CN110678472A (zh) 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物
TWI891227B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
HK1246779A1 (zh) 作为磷酸肌醇3-激酶抑制剂的色烯衍生物
CN111868036A (zh) 杂环p2y14受体拮抗剂
EP4072670B1 (en) Quinazoline derivatives as lpa receptor 2 inhibitors
JP2024512557A (ja) Ｌｐａ受容体２阻害物質としての８－シクロ－置換キナゾリン誘導体
HK40029587B (zh) 化合物、组合物及方法
TW202220978A (zh) 雜環化合物
HK40091436A (zh) 作为a2a抑制剂的2-氧代噻唑衍生物和用於治疗癌症的化合物
HK40061670A (en) Compounds and compositions for treating conditions associated with apj receptor activity
HK40012938A (en) Tyrosine amide derivatives as rho- kinase inhibitors
HK40012938B (en) Tyrosine amide derivatives as rho- kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201030

WD01 Invention patent application deemed withdrawn after publication